Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
Recruiting · NCT05745857 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas | Barrett esophagus, Digestive System Diseases, digestive system disorder, esophageal adenocarcinoma, esophageal disorder, neoplasm, precancerous condition | Recruiting | Phase 2 | 2026-04-13 | NCT05745857 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University Medical Center Groningen | 213 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Medical Center Groningen | Groningen | Netherlands | 16 |